Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?
Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission